https://orcid.org/0000-0002-1342-4692
Research Interests
Breast Oncology
Clinical Trial Development
Clinical Trial Development
Selected Grants
A Phase 1b/2, Open-label, Multicenter, Multi Arm Study of Evorpacept in Combination with Anti-cancer Therapies in Advanced / Metastatic Malignancies (ASPEN-09)
Clinical TrialPrincipal Investigator · Awarded by ALX Oncology Inc. · 2026 - 2031Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence?A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)?
Clinical TrialPrincipal Investigator · Awarded by Stemline Therapeutics, Inc · 2025 - 2030A Phase 3, randomized, open-label, controlled study comparing the efficacy and safety of zanidatamab to trastuzumab, each in combination with physician's choice chemo, for the treatment of participants with metastatic HER2-positive breast cancer
Clinical TrialPrincipal Investigator · Awarded by Jazz Pharmaceuticals · 2025 - 2030A Phase III, Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared with Fulvestrant, Both Combined with a CDK4/6 Inhibitor, in Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer with Resist...
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2024 - 2029A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembroliz
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2024 - 2029An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre-and Postmenopausal Women and Men with Locally
Clinical TrialPrincipal Investigator · Awarded by Sermonix Pharmaceuticals · 2024 - 2028CAMBRIA-1:ER+/HER2- Early Stage Breast Cancer being treated with Endocrine Therapy after Surgery
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2024 - 2028External Relationships
- Aztra Zeneca
- CareSpace Health Inc
- Gilead Sciences, Inc.
- Interact Health
- NCODA
- NoeticInsight
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.